Liminatus Pharma, Inc.
LIMN
$6.15
-$0.15-2.38%
NASDAQ
| 12/31/2024 | 03/31/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Net Income | -229.00K | -1.75M | -771.00K | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -- | -- | -- | ||
| Change in Net Operating Assets | 88.00K | 882.00K | 452.00K | ||
| Cash from Operations | -141.00K | -872.00K | -319.00K | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -550.00K | -700.00K | -469.00K | ||
| Cash from Investing | -550.00K | -700.00K | -469.00K | ||
| Total Debt Issued | 700.00K | 1.20M | 1.40M | ||
| Total Debt Repaid | -- | -- | -200.00K | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -36.00K | -- | ||
| Cash from Financing | 700.00K | 1.16M | 1.20M | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 9.00K | -408.00K | 412.00K | ||